Smolock Elaine M, Trappanese Danielle M, Chang Shaohua, Wang Tanchun, Titchenell Paul, Moreland Robert S
Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N. 15th St., MS #488, Philadelphia, PA 19102, USA.
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1930-9. doi: 10.1152/ajpheart.00129.2009. Epub 2009 Sep 18.
Smooth muscle contraction involves phosphorylation of the regulatory myosin light chain. However, this thick-filament system of regulation cannot account for all aspects of a smooth muscle contraction. An alternate site of contractile regulation may be in the thin-filament-associated proteins, in particular caldesmon. Caldesmon has been proposed to be an inhibitory protein that acts either as a brake to stop any increase in resting or basal tone, or as a modulatory protein during contraction. The goal of this study was to use short interfering RNA technology to decrease the levels of the smooth muscle-specific isoform of caldesmon in intact vascular smooth muscle tissue to determine more carefully what role(s) caldesmon has in smooth muscle regulation. Intact strips of vascular tissue depleted of caldesmon produced significant levels of shortening velocity, indicative of cross-bridge cycling, in the unstimulated tissue and exhibited lower levels of contractile force to histamine. Our results also suggest that caldesmon does not play a role in the cooperative activation of unphosphorylated cross bridges by phosphorylated cross bridges. The velocity of shortening of the constitutively active tissue and the high basal values of myosin light chain phosphorylation suggest that h-caldesmon in vivo acts as a brake against contractions due to basally phosphorylated myosin. It is also possible that phosphorylation of h-caldesmon alone in the resting state may be a mechanism to produce increases in force without stimulation and increases in calcium. Disinhibition of h-caldesmon by phosphorylation would then allow force to be developed by activated myosin in the resting state.
平滑肌收缩涉及调节性肌球蛋白轻链的磷酸化。然而,这种粗肌丝调节系统无法解释平滑肌收缩的所有方面。收缩调节的另一个位点可能存在于细肌丝相关蛋白中,特别是钙调蛋白。钙调蛋白被认为是一种抑制性蛋白,它要么作为制动器阻止静息或基础张力的任何增加,要么在收缩过程中作为调节蛋白。本研究的目的是使用短干扰RNA技术降低完整血管平滑肌组织中平滑肌特异性钙调蛋白异构体的水平,以更仔细地确定钙调蛋白在平滑肌调节中所起的作用。去除钙调蛋白的完整血管组织条在未受刺激的组织中产生了显著水平的缩短速度,这表明存在横桥循环,并且对组胺的收缩力水平较低。我们的结果还表明,钙调蛋白在磷酸化横桥对未磷酸化横桥的协同激活中不起作用。组成型活性组织的缩短速度以及肌球蛋白轻链磷酸化的高基础值表明,体内的h-钙调蛋白作为对由于基础磷酸化肌球蛋白引起的收缩的制动器。也有可能在静息状态下单独h-钙调蛋白的磷酸化可能是一种在无刺激和钙增加的情况下产生力增加的机制。通过磷酸化对h-钙调蛋白的去抑制将允许在静息状态下由活化的肌球蛋白产生力。